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SUMMARY
Guidelines recommend praziquantel (PZQ) for the treatment and control of schistosomiasis, with no real alternative.
Metrifonate was still widely used against Schistosoma haematobium in the 1990s, and then withdrawn. Experimental studies
and clinical trials suggest that artemisinin compounds are active against S. haematobium. In a Cochrane systematic review
assessing the eﬃcacy and safety of drugs for treating urinary schistosomiasis, 24 randomized controlled trials (n=6315
individuals) met our inclusion criteria. These trials compared a variety of single agent and combination regimens with PZQ,
metrifonate or artemisinin derivatives. The review conﬁrmed that both the standard recommended doses of PZQ (single
40 mg/kg oral dose) and metrifonate (3r7.5–10 mg/kg oral doses administered fortnightly) are eﬃcacious and safe in
treating urinary schistosomiasis, but there is no study comparing these two regimens head-to-head. There is currently not
enough evidence to evaluate artemisinin compounds. Most of the studies included in the Cochrane systematic review were
insuﬃciently powered, lacked standardization in assessing and reporting outcomes, and had a number of methodological
limitations. In this paper we discuss the implications of these ﬁndings with respect to public health and research method-
ology and propose priority research needs.
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INTRODUCTION
Schistosomiasis is a common parasitic disease in the
tropics and subtropics. An estimated 779 million
individuals are at risk of acquiring schistosomiasis
and more than 200 millions were infected in mid-
2003 (Steinmann et al. 2006). The World Health
Organization (WHO) estimates that the global
burden due to schistosomiasis may be as high as
4.5 million disability-adjusted life years (DALYs)
(WHO, 2002). However, a meta-analysis suggests
that disability weights might be 2–15 times higher
than those used in the global burden of disease study
(King, Dickman and Tisch, 2005), and that the
DALY underestimates the importance of chronic
diseases like schistosomiasis (King and Bertino,
2008). This is further substantiated by the results of
approaches using a quality of life questionnaire and
decision-tree modelling (Jia et al. 2007; Finkelstein
et al. 2008). From a public health perspective, the
three most important schistosome species are
Schistosoma haematobium (causing urinary schisto-
somiasis), and S. mansoni and S. japonicum (causing
intestinal schistosomiasis).
Two drugs, metrifonate and praziquantel (PZQ),
have been used extensively for urinary schisto-
somiasis (Cioli, Pica-Mattoccia and Archer, 1995;
Utzinger and Keiser, 2004). However, in the late
1990s, metrifonate was withdrawn from the WHO
model list of essential medicines because it was
considered clinically, economically and operationally
inferior to PZQ as it is only active against S. hae-
matobium, requires multiple administrations, and
hence is less convenient in large-scale control pro-
grammes (Feldmeier and Chitsulo, 1999). Thus,
PZQ remains the only drug for clinical management
and community-based control of schistosomiasis
(Cioli, 2000; Fenwick et al. 2003; Utzinger and
Keiser, 2004; Caﬀrey, 2007; Doenhoﬀ, Cioli and
Utzinger, 2008). Large-scale morbidity control pro-
grammes became feasible as the price of PZQ fell
from approximately US$ 1.0 in the 1980s to less than
US$ 0.1 per 600 mg tablet (Fenwick et al. 2003;
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Fenwick, Keiser and Utzinger, 2006; Doenhoﬀ et al.
2008). Paradoxically, this also stalled investments in
the discovery and development of alternative control
measures, such as other drugs, vaccines and diag-
nostics (Utzinger et al. 2007; Bergquist, Utzinger
and McManus, 2008). Research carried out over
the past 15 years revealed the antischistosomal
properties of artemisinin derivatives, which act
especially on the young developing stages of the
parasites (for a recent review seeUtzinger et al. 2007)
as opposed to PZQ, which acts against the adult
worms and the very young schistosomula just after
skin penetration (Sabah et al. 1986; Utzinger et al.
2007).
The use of PZQ has increased considerably after
the 54th World Health Assembly set the target of
at least 75% of school-aged children and other high-
risk groups to be treated regularly with PZQ by
2010 in areas where the disease is highly endemic
(WHO, 2002). At least 17 million doses of PZQ
have been administered, primarily to school-aged
children in selected African countries, since the
launch of the ‘Schistosomiasis Control Initiative’
in 2003 (Fenwick et al. 2006). Relying on prazi-
quantel alone for controlling a disease that aﬀects
millions of people is risky should resistance develop
against this drug (Danso-Appiah and de Vlas, 2002;
Doenhoﬀ et al. 2008).
In the light of this, we assessed the eﬀects of PZQ
and other antischistosomal treatments by conducting
a Cochrane systematic review, including compar-
isons between PZQ and metrifonate and trials of
combination treatments. During this process, we
identiﬁed a number ofmethodological issues relevant
to the interpretation of existing data that might help
researchers to design more appropriate trials in the
future. The full review is available on the Cochrane
Library (Danso-Appiah et al. 2008). In this paper
we highlight key ﬁndings of the review, discuss im-
plications of various methodological limitations and
consider future research needs.
SUMMARY OF COCHRANE SYSTEMATIC REVIEW
Inclusion criteria and search strategy
To qualify for inclusion, a study was (1) to be con-
trolled, randomized or quasi-randomized, enrolling
individuals infected with S. haematobium, as deter-
mined microscopically for S. haematobium eggs in a
standard ﬁltrate of 10 ml of urine or by haematuria
(Feldmeier and Poggensee, 1993) ; and (2) to treat
patients with either PZQ, metrifonate or artemisinin
derivatives. An extensive, standard search was car-
ried out, which included MEDLINE (1966 to
August 2007), EMBASE (1974 to August 2007),
LILACS (1982 to August 2007), conference pro-
ceedings and contacting specialists in the ﬁeld
(Danso-Appiah et al. 2008).
Data retrieval, quality assessment and analysis
Eligibility and methodological quality of the ident-
iﬁed trials were assessed by the authors and the data
analysed using Review Manager 4.2 (The Cochrane
Collaboration, 2003). The main outcome measure
was failure rate (the proportion of individuals re-
maining positive for eggs in their urine at follow-up).
Comparisons between groups were expressed as rela-
tive risk (RR) with 95% conﬁdence intervals (CIs)
for both individual studies and on aggregate. The
secondary parameter was egg reduction rate and was
analysed using weighted mean diﬀerence with stan-
dard error. The proportion of patients with adverse
events was compared between treatment and control
arms.
Key ﬁndings of the Cochrane systematic review
The search identiﬁed 24 randomised controlled trials
that together involved 6315 participants. Table 1
summarises key characteristics of these 24 trials.
When used as monotherapy, both metrifonate and
PZQ showed obvious beneﬁt in terms of parasito-
logical outcomes (Danso-Appiah et al. 2008). One
trial (120 participants) of artesunate showed no ob-
vious beneﬁt over placebo.
For combination treatments, one trial studied the
combination of PZQ with artesunate, but there was
no obvious advantage over PZQ alone.
Metrifonate versus PZQ: comparisons and
dose eﬀects
Fig. 1 summarises the failure rate of metrifonate
versus PZQ in the ﬁve trials meeting our inclusion
criteria (McMahon, 1983; Pugh and Teesdale, 1983;
Wilkins and Moore, 1987; King et al. 1988;
Stephenson et al. 1989).
When metrifonate was introduced, some early
studies investigated a single dose of 10 mg/kg (the
standard dose is 7.5 to 10 mg/kg three times at 14-day
intervals) versus the standard single dose of 40 mg/kg
PZQ. Although the single metrifonate dose was in-
ferior in three trials measuring failure at one to eight
months, the 95% CIs were too wide for statistical
signiﬁcance (RR=2.31, 95% CI: 0.91–5.82; n=462
participants). This lack of signiﬁcance is due to sig-
niﬁcant heterogeneity between trials (I2=94%) likely
to be associated with the duration of follow-up: the
RR was 1.26 at one month of follow-up (Pugh and
Teesdale, 1983), 2.23 at three months (Wilkins and
Moore, 1987) and 4.62 at eight months (Stephenson
et al. 1989).
There was no signiﬁcant diﬀerence in failure rates
when metrifonate given as multiple doses (3r
10 mg/kg fortnightly) was compared with PZQ
(30 mg/kg) in a small trial involving 54 participants
(McMahon, 1983). A trial comparing three doses
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Table 1. Summary of the characteristics of randomised controlled trials included in our Cochrane systematic review (Danso-Appiah et al. 2008) evaluating
antischistosomal drugs, used alone or in combination, for treating urinary schistosomiasis
Reference and
country where
trial was
implemented
Year trial
was
conducted N*
Age of
participants
Diagnostic
approach**
Endemicity
(prevalence)
Sample
size Intervention
Outcome
measures
Brand
of drug
Follow-up
(months)
Quality assessment
Generation
of
allocation
sequence
Allocation
concealment Blinding
Loss to
follow-up
Aden Abdi and
Gustafsson
(1989);
Somalia
Not
reported
5 Children:
mean age of
14 years
Urine ﬁltration
(10 ml;
1 specimen)
Very high 300 1. Metrifonate
(7.5 mg/kgr3 given
at 2-week intervals)
2. Metrifonate
(5 mg/kgr3 given
in 1 day)
1. Cure rate
2. Egg reduction
rate
3. Adverse events
Metrifonate
(Bilarcil, Bayer)
1, 2, 3 and 6 Adequate Adequate Investigators,
participants
and assessors
33% at 2 months
Beasley et al.
(1999);
Tanzania
1994 1 Children:
7–12 years
Urine ﬁltration
(10 ml;
1 specimen)
High (56%) 357 1. PZQ (40 mg/kgr1)
plus albendazole
(400mgr1)
2. Placebo
1. Cure rate
2. Egg reduction
rate
3. Mean haemo-
globin
PZQ (Biltricide,
Bayer)
3.75 Adequate Unclear Outcome
assessors
30%
Beﬁdi-Mengue
et al. (1992);
Cameroon
Not
reported
1 Boys:
6–15 years
Urine ﬁltration
(10 ml;
1 specimen)
Not
reported
436 1. PZQ (40 mg/kgr1)
2. Placebo
1. Anaemia
2. Physical growth
3. Haematuria
4. Proteinuria
Not stated 6 Unclear Unclear Unclear Unclear
Borrmann
et al. (2001);
Gabon
Not
reported
3 Children:
5–13 years
Urine ﬁltration
(10 ml;
2 specimens)
Very high
(80%)
300 1. PZQ (40 mg/kgr1)
2. Artesunate (4 mg/
kg/day for 3 days)
3. PZQ (40 mg/kgr1)
plus artesunate
(4 mg/kg/day over 3
days)
4. Placebo
1. Cure rate
2. Adverse events
3. Resolution of
haematuria
4. Egg reduction
rate
Not stated 8 Adequate Adequate Participants and
investigators
1.3%
Davis et al.
(1981);
Zambia
Not
reported
1 Children
and young
adults:
7–22 years
Urine ﬁltration
(10 ml;
3 specimens)
Not
reported
79 1. PZQ
(20 mg/kgr1)
2. PZQ
(30 mg/kgr1)
3. PZQ (40 mg/kgr1)
4. PZQ
(20 mg/kgr2)
5. Placebo
1. Adverse events
2. Cure rate
3. Mean
haemoglobin
Not stated 1, 6, 9 and
12
Adequate Adequate Participants,
investigators
and outcome
assessors
7.6% and 16.5%
at 6 and 12
months,
respectively
Doehring et al.
(1985);
Sudan
Not
reported
1 Boys:
6–13 years
Urine ﬁltration
(10 ml;
3 specimens)
Very high 182 1. PZQ (40 mg/kgr1)
2. Metrifonate (10 mg/
kgr3 given at
2-week intervals)
3. Placebo
1. Egg reduction
rate
2. Proteinuria
Not stated 1 Unclear Unclear Unclear 0%
Jewsbury and
Cooke
(1976);
Zimbabwe
Not
reported
4 Children
(age not
speciﬁed)
Urine ﬁltration
(10 ml;
1 specimen vs.
3 specimens)
Very high
(80%)
179 1. Metrifonate
(7.5 mg/kgr3 given
at 2-week intervals)
2. Placebo
(Third arm excluded
from current review)
1. Cure rate
2. Egg reduction
rate
3. Adverse events
Metrifonate
(Bilarcil, Bayer)
1.2, 7 and 16 Adequate Unclear Unclear Not reported
Jinabhai et al.
(2001); South
Africa
Not
reported
11 Children:
8–10 years
Not stated High 268 1. PZQ (40 mg/kgr1)
plus albendazole
(400 mgr1)
2. Placebo
(Another arm consisted
of albendazole
(400 mgr1)
for intestinal
helminths)
1. Cure rate Not stated 4 Unclear Unclear Unclear Not reported
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Table 1. (cont.)
Reference and
country where
trial was
implemented
Year trial
was
conducted N*
Age of
participants
Diagnostic
approach**
Endemicity
(prevalence)
Sample
size Intervention
Outcome
measures
Brand
of drug
Follow-up
(months)
Quality assessment
Generation
of
allocation
sequence
Allocation
concealment Blinding
Loss to
follow-up
Kardaman
et al. (1985);
Sudan
Not
reported
Not
reported
Children:
7–11 years
Urine ﬁltration
(10 ml;
2 specimens)
Not
reported
237 1. PZQ (40 mg/kgr1)
2. PZQ (20 mg/kgr2)
1. Adverse events
2. Cure rate
3. Egg reduction
rate
Not reported 1, 3, 6 and
12
Unclear Unclear Unclear 7.3%
King et al.
(1988);
Kenya
Not
reported
Not
reported
Children
and young
adults:
4–21 years
Urine ﬁltration
(10 ml;
2 specimens)
Not
reported
2628 1. Metrifonate (10 mg/
kgr3 given at
4-month intervals)
2. PZQ (40 mg/kgr1)
1. Haematuria
2. Proteinuria
(Other arms
not relevant
for current
review, hence
were excluded)
Metrifonate
(Bilarcil, Bayer);
PZQ (Biltricide
Bayer)
12 Adequate Unclear Participants and
assessors
23%
King et al.
(1989);
Kenya
Not
reported
Not
reported
Children
and adults
(age not
speciﬁed)
Urine ﬁltration
(10 ml;
2 specimens)
Very high 280 1. PZQ (40 mg/kgr1)
2. PZQ (30 mg/kgr1)
3. PZQ (20 mg/kgr1)
4. PZQ (10 mg/kgr1)
1. Cure rate
2. Egg reduction
rate
3. Haematuria
4. Proteinuria
Not reported 3 Adequate Unclear Unclear 14%
King et al.
(2002);
Kenya
1993 2 Children
and young
adults:
4–23 years
Urine ﬁltration
(10 ml;
2 specimens)
Very high
(80%)
291 1. PZQ (40 mg/kgr1)
2. PZQ (20 mg/kgr1)
1. Cure rate
2. Egg reduction
rate
3. Haematuria
4. Proteinuria
Not reported 2.5 and 9 Adequate Unclear Clinicians and
assessors
31%
McMahon and
Kolstrup
(1979);
Tanzania
Not
reported
1 Children:
7–15 years
Urine ﬁltration
(10 ml;
3 specimens)
Not
reported
183 1. PZQ (30 mg/kgr1)
2. PZQ (40 mg/kgr1)
3. PZQ (20 mg/kgr2)
4. Placebo
1. Cure rate
2. Egg reduction
rate
3. Adverse events
PZQ (Biltricide,
Bayer)
1, 3 and 6 Unclear Unclear Unclear 31%, 32% and
36% at 1, 3 and
6 months,
respectively
McMahon
(1983);
Tanzania
Not
reported
1 Children
and adults
(age not
speciﬁed)
Urine ﬁltration
(10 ml;
3 specimens)
Not
reported
90 1. Metrifonate (10 mg/
kgr3 given at
2-week intervals)
2. PZQ (30 mg/kgr1)
(Third arm consisting
of niradazole was
excluded)
1. Cure rate
2. Egg reduction
rate
3. Adverse events
Not reported 2 and 4 Unclear Unclear Unclear 14% and 31% at
2and4months,
respectively
Olds et al.
(1999);
Kenya
Not
reported
1 Children:
4–18 years
Urine ﬁltration
(10 ml;
2 specimen vs.
10 ml;
1 specimen)
Very high 380 1. PZQ (40 mg/kgr1)
plus
albendazole
(400 mgr1)
2. PZQ plus
albendazole
placebo
3. Albendazole plus
PZQ placebo
4. Both placebos
1. Physical growth
2. Haemoglobin
3. Failure rate
4. Egg reduction
rate
5. Adverse eﬀects
Not reported 1.5, 3, 6 and
12
Adequate Adequate Participants and
assessors
1%, 1%, 10%
and 17% at 1.5,
3, 6 and 12
months,
respectively
Omer (1981);
Sudan
1978–79 1 Children
(>8 years)
and adults
Urine ﬁltration
(10 ml;
1 specimen)
Very high 153 1. PZQ (30 mg/kgr1)
2. PZQ (40 mg/kgr1)
3. PZQ (20 mg/kgr2)
1. Adverse events
2. Cure rate
3. Egg reduction
rate
PZQ (Biltricide,
Bayer)
6 Unclear Unclear Unclear 20%
Oyediran et al.
(1981);
Nigeria
Not
reported
1 Children:
9–16 years
Urine ﬁltration
(10 ml;
3 specimens)
Light to
moderate
90 1. PZQ (30 mg/kgr1)
2. PZQ (40 mg/kgr1)
3. PZQ (20 mg/kgr2)
4. Placebo
1. Egg reduction
rate
2. Adverse events
PZQ (Biltricide,
Bayer)
1, 3 and 6 Unclear Unclear Unclear 31.7%, 32.3%
and 36% at 1,
3and6months,
respectively
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Table 1. (cont.)
Reference and
country where
trial was
implemented
Year trial
was
conducted N*
Age of
participants
Diagnostic
approach**
Endemicity
(prevalence)
Sample
size Intervention
Outcome
measures
Brand
of drug
Follow-up
(months)
Quality assessment
Generation
of
allocation
sequence
Allocation
concealment Blinding
Loss to
follow-up
Pugh and
Teesdale
(1983);
Malawi
Not
reported
Not
reported
Children:
5–18 years
Urine ﬁltration
(10 ml;
1 specimen)
Not
reported
600 1. PZQ (40 mg/kgr1)
2. Metrifonate (10 mg/
kgr1)
3. Placebo
1. Cure rate
2. Egg reduction
rate
3. Adverse events
Metrifonate
(Bilarcil, Bayer);
PZQ (Biltricide,
Bayer)
1, 3 and 6 Inadequate Unclear Participants,
clinicians and
assessors
3% at 1 month
Rey et al.
(1983); Niger
Not
reported
3 Children
and adults
(age not
speciﬁed)
Urine ﬁltration
(10 ml;
1 specimen)
High (50%) 103 1. Metrifonate (10 mg/
kgr1)
2. Metrifonate (10 mg/
kgr2 given
fortnightly)
3. Metrifonate (10 mg/
kgr3 given
fortnightly)
1. Cure rate
2. Egg reduction
rate
Not reported 1, 3 and 6 Adequate Unclear Unclear 9.7%, 6.4% and
8.1% at 1, 3
and 6 months,
respectively
Rey, Nouhou
and Sellin
(1984); Niger
Not
reported
3 Children
and adults
(age not
speciﬁed)
Urine ﬁltration
(10 ml;
1 specimen)
Not
reported
286 1. Metrifonate (10 mg/
kgr1)
2. Metrifonate (10 mg/
kgr2 given
fortnightly)
3. Metrifonate (10 mg/
kgr3 given
fortnightly)
1. Cure rate
2. Egg reduction
rate
Not reported 2 and 4 Unclear Unclear Unclear 50% and 38.8%
at 2 and 4
months,
respectively
Stephenson
et al. (1985);
Kenya
Not
reported
1 Children:
6–15 years
Urine ﬁltration
(10 ml of urine
adjusted for whole
volume)
Moderate
(46%)
400 1. Metrifonate
(7.5 mg/kgr3 given
fortnightly)
2. Placebo
1. Cure rate
2. Splenomegaly
3. Hepatomegaly
4. Egg reduction
rate
5. Haemoglobin
6. Anthropometric
measurements
Not reported 8 Unclear Unclear Assessors Not reported
Stephenson
et al. (1989);
Kenya
Not
reported
Not
reported
Children
(age not
speciﬁed)
Urine ﬁltration
(10 ml of urine
adjusted for whole
volume)
Light to
moderate
347 1. Metrifonate (10 mg/
kgr1)
2. PZQ (40 mg/kgr1)
3. Placebo
1. Cure rate
2. Egg reduction
rate
3. Physical growth
Not reported 8 Unclear Unclear Assessors 10%
Taylor,
Murare and
Manomano
(1988);
Zimbabwe
Not
reported
1 Children:
10–15 years
Urine ﬁltration
(10 ml;
3 specimens)
Very high
(77%)
373 1. PZQ (10 mg/kgr1)
2. PZQ (20 mg/kgr1)
3. PZQ (30 mg/kgr1)
4. PZQ (40 mg/kgr1)
5. Placebo
1. Cure rate
2. Egg reduction
rate
Not reported 1, 3 and 6 Unclear Unclear Assessors No losses
reported
Wilkins and
Moore
(1987);
Gambia
Not
reported
3 Children:
2–19 years
Urine ﬁltration
(10 ml;
3 specimens)
Very high 184 1. PZQ (40 mg/kgr1)
2. PZQ (20 mg/kgr1)
3. PZQ (10 mg/kgr1)
4. Metrifonate (10 mg/
kgr1)
5. Metrifonate (10 mg/
kgr1) plus PZQ
(10 mg/kgr1)
1. Egg reduction
rate
2. Adverse events
Not reported 3 Adequate Unclear Assessors No losses
reported
* N – Number of communities involved in the trial.
** For urine ﬁltration, 10 ml; 3 specimen vs. 10 ml; 1 specimen means pre- and post-treatment diagnosis varied; i.e. pre-treatment diagnosis involved 10 ml and 3 specimen but 10 ml and 1 specimen for post-treatment assessment.
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of metrifonate at 10 mg/kg given once every four
months with the standard 40 mg/kg PZQ (single
dose) in school-aged children in Kenya detected no
diﬀerence overall, but metrifonate was superior in
the subgroup of children with a heavy infection
(RR=0.88, 95% CI: 0.80–0.96; n=615 partici-
pants). However, as the subgroup was stratiﬁed after
randomisation, this result should be interpreted with
caution. Both metrifonate (two and three doses of
10 mg/kg) and PZQ (single dose 40 mg/kg) led to
very high reductions in egg excretion (>98%) in two
trials (McMahon, 1983; Doehring et al. 1985).
One trial (n=54 participants) compared adverse
events and reported similar minor events between
metrifonate (3r10 mg/kg) and PZQ (30 mg/kg); no
serious adverse events were noted (McMahon, 1983).
Mild and transient abdominal pain was more com-
monwith triplicatemetrifonate than single dose PZQ
(75% versus 30%), but the dose of PZQ used (30 mg/
kg) was lower than the one currently recommended
(40 mg/kg) (WHO, 2002).
Metrifonate: dose comparisons
One trial with 201 participants compared 3r
5 mg/kg metrifonate administered in a single day
to 3r7.5 mg/kg given fortnightly (Aden Abdi and
Gustafsson, 1989).Therewas no signiﬁcant diﬀerence
in parasitological failure and egg reduction rate; the
geometric mean egg reduction rate was 96% for the
one-day regimen and 97% for the fortnightly regi-
men. There was little diﬀerence in the percentage of
patients with mild adverse events reported for the
fortnightly regimen (7%) versus the one-day regi-
men (9%).
Three doses of metrifonate (10 mg/kg) were com-
pared with one and two doses (Rey, Nouhou and
Sellin, 1984). There was no signiﬁcant diﬀerence in
parasitological failure rates between two and three
doses at one month and four months follow-up.
Similarly, no signiﬁcant diﬀerences in failure rate and
egg reduction rates were detected between two and
three doses of 10 mg/kg, given fortnightly in a trial of
81 participants (Rey et al. 1984). By contrast, there
were fewer parasitological failures with the three-
dose regimen over the one dose regimen at the one
month follow-up (RR=2.75, 95% CI: 1.29–5.85;
n=93 participants) and the four-month follow-up
(RR=1.52, 95%CI: 1.03–2.25; n=111 participants).
Diﬀerent PZQ doses versus standard regimen
(1r40 mg/kg)
Ten trials compared the standard regimen of PZQ
(single dose of 40 mg/kg) to various other doses
(McMahon and Kolstrup, 1979; Davis et al. 1981;
1 2 5 10
2.23 (1.39, 3.86)
4.62 (2.83, 7.74)
1.26 (1.05, 1.53)
2.31 (0.91, 5.82)
Relative risk (95% confidence interval)
Source
Pugh and Teesdale (1983)a
Stephenson et al. (1989)a
Wilkins and Moore (1987)a
Relative risk
(95% confidence interval)
0.5
1.88 (0.60, 5.90)
1.88 (0.60, 5.90)
McMahon (1983)b
1.19 (0.94, 1.51)
1.19 (0.94, 1.51)
King et al. (1988)c
Combined (random-effects model)
No. not cured / total no.
Metrifonate
(1x 10 mg/kg)
Praziquantel
(1x 40 mg/kg)
72/90 58/93
64/103 14/104
29/39 11/33
Source
Metrifonate
(3x 10 mg/kg; 2 we)
Praziquantel
(1x 30 mg/kg)
6/24 4/30
Metrifonate
(3x 10 mg/kg; 4 mo)
Praziquantel
(1x 40 mg/kg)
120/620 101/621
Total (random-effects model)
Source
Total (random-effects model)
Favours praziquantelFavours metrifonate
a Evaluation 1-8 mo post-treatment; b Evaluation 2 mo post-treatment; c Evaluation 12 mo post-treatment
Fig. 1. Risk ratio estimates (combined or total) of randomized controlled trial(s) of metrifonate (diﬀerent regimens)
versus PZQ (single dose, 30 mg/kg or 40 mg/kg) against S. haematobium. Rectangles represent risk ratios and sizes of the
rectangles denote the weight given to each trial in the meta-analysis. Diamond and vertical broken line indicate
combined (total) relative risk (RR). Horizontal lines indicate 95% conﬁdence intervals. The dashed vertical line is the
null value (RR=1; neither favouring metrifonate nor PZQ). Abbreviations: mo, month; we, week.
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Omer, 1981; Oyediran et al. 1981; Rey et al. 1983;
Kardaman et al. 1985; Wilkins and Moore, 1987;
Taylor, Murare and Manomano, 1988; King et al.
1989, 2002). In terms of parasitological failure, there
was no signiﬁcant diﬀerence between the standard
regimen and 2r20 mg/kg (4 trials), a single dose of
30 mg/kg (6 trials), and a single dose of 20 mg/kg
(2 trials). Similar results were found at one, three
and six months follow-up. Losses to follow-up were
generally high, but these did not diﬀer across treat-
ment and control groups within a single trial. There
was no signiﬁcant heterogeneity between the trials,
and background endemicity did not seem to play
a role. Examining for a diﬀerential eﬀect between
heavy andmoderate or light infections with 30 mg/kg
versus standard 40 mg/kg, a subgroup analysis of
one small trial (King et al. 1989) did not show any
diﬀerence (n=116 participants). Five trials showed
no apparent diﬀerences in egg reduction rate (geo-
metric mean); all had greater than 95% reduction in
both arms.
Artesunate
Thus far, only one randomised controlled trial con-
ducted in Gabon in schoolchildren compared the
eﬀects of artesunate combined with PZQ to each
individual drug given as monotherapy (Borrmann
et al. 2001). Whilst the artesunate-PZQ combination
resulted in a relatively higher egg reduction rate, it
was not possible to identify an eﬀect of artesunate, as
no signiﬁcant diﬀerence was observed in cure rates
when compared to PZQ alone.
METHODOLOGICAL LIMITATIONS
Lack of standardization and quality data for the as-
sessment of eﬃcacy and safety of antischistosomal
drugswas reported previously forS.mansoni (Danso-
Appiah and de Vlas, 2002). In this Cochrane
systematic review (Danso-Appiah et al. 2008), we
identiﬁed a number of methodological limitations
that raise issues with trial quality and the potential for
bias, outlined below. Some of the shortcomings
have implications for the interpretation of trials in
schistosomiasis and other tropical diseases (responses
to methodological limitations summarised in Box 1).
(1) Some trials had no proper sample size calcu-
lation: this suggests the authors may not have con-
sidered whether their study was suﬃciently powered
to answer the question being posed. (2) Random-
isation quality was not high: only four out of 24 trials
(17%) met quality standards for adequate conceal-
ment of allocation and described the methods used
(for quality standards see Ju¨ni, Altman and Egger
(2001) and Higgins and Green (2008). Trials con-
ducted in the early 1990s and earlier did not conceal
allocation except one (Davis et al. 1981). Generation
of allocation sequence was adequate in less than
half of the trials included in our meta-analysis. For
the others, the method used was unclear although
all were reported as randomized controlled trials.
(3) Losses to follow-up were often high in some
trials, and increased proportionally with the duration
of follow-up: 17 trials registered losses of<10% for
short-term evaluations at one to three months, but
losses reached up to 50% in some trials when follow-
up time was longer than three months. (4) Diagnostic
criteria were varied, vague and not standardised:
among the trials included in our meta-analysis, the
criteria for diagnosis varied greatly ; some trials used
three urine specimens on three consecutive days for
microscopic examination, whilst others used a single
specimen (Table 1). In some trials sampling criteria
varied even between pre- and post-treatment using
microscopy (e.g. three urine specimens for the pre-
treatment diagnosis but only one for post-treatment
follow-up assessment) while other trials lacked any
criteria for diagnosis. (5) Classiﬁcation of infection
intensities lacked standardization: Table 2 shows con-
siderable variation in the classiﬁcation of infection
Box 1. Responses to methodological limitations of
trials included in a Cochrane review of drugs for
treating urinary schistosomiasis (Danso-Appiah
et al. 2008)
Design issues
1. There is the need for a uniﬁed study method-
ology in the design, collection and reporting of
trials.
2. Trialists should be sensitized to the importance
of proper sample size calculation to ensure that
trials are suﬃciently powered. High losses to
follow-up in trials with small sample sizes fur-
ther compromise the statistical power.
3. There is the need to describe the randomisation
procedure clearly.
4. There is a need for standardized, quality-
controlled diagnostic criteria within and between
trials.
5. In high endemicity areas a follow-up time of 4 to
8 weeks is appropriate when investigating cure
rates to avoid eggs released from dead worms and
minimise the eﬀect of re-infection.
Interpretation and reporting
6. Intensity of infection and egg reduction rate
(ERR) should be reported in geometric mean,
and intensity of infection should be based on egg
count of only the positive cases and reported
using the standard classiﬁcation by the WHO
(WHO, 2002).
7. Treatment outcomes need to be clearly deﬁned
and standardised across trials. Parasitological
outcomes should be reported with; (a) level of
edemicity, (b) diagnostic criteria, (c) dose used,
(d) age of participants and (e) follow-up time.
Treatment of urinary schistosomiasis 1843
intensity across trials. According to current WHO
guidelines, infection intensity of S. haematobium is
either light (1–49 eggs/10 ml of urine) or heavy (o50
eggs/10 ml of urine) (WHO, 2002). In the trials in-
cluded in our meta-analysis, however, light infec-
tions were variably classiﬁed as 1–5, 1–29, 1–99,
60–249 or even 250–500 eggs/10 ml of urine. Ac-
cordingly, moderate and heavy infections varied
from one trial to another. (6) Outcomes were re-
ported in a variety of ways: in our review we deﬁned
primary outcomes as (i) parasitological failure and
(ii) egg reduction rate. However, these two measures
were variably reported as cure rate, failure rate,
cumulative failure rate or prevalence for parasito-
logical failure, and as a median, arithmetic mean
or geometric mean for egg reduction rate. Even the
calculation of geometric mean varied; some inves-
tigators considered only the egg-positive individuals,
whilst others included the negatives and introduced
a correction factor of plus 1. The latter becomes
problematic after treatment when most of the re-
maining infections are light, as it may overestimate
egg count values. (7) Timing of post-treatment as-
sessments varied greatly: the majority of trials evalu-
ated cure and egg reduction rate within one to
three months; however, some trials did so at three
weeks or earlier, or only six or even 12 months post-
treatment. Results from studies on urinary schisto-
somiasis assessing outcomes earlier than three weeks
or beyond three months post-treatment should be
considered with caution. The reasons are that the
development of S. haematobium worms takes ap-
proximately two months (Ghandour, 1978); shorter
follow-up is confounded by eggs of killed worms still
being excreted, longer follow-up by re-infections,
particularly in highly endemic settings (N’Goran
et al. 2001; Tchuem Tchuente´ et al. 2004;
Satayathum et al. 2006). Noteworthy, most of the
trials in this review were conducted in high endem-
icity areas and there was no way in diﬀerentiating
between re-infection and recrudescence.
DISCUSSION
Public health implications
Despite the above-mentioned methodological limi-
tations, the ﬁndings of our Cochrane systematic
review have important public health implications.
One of the most important ﬁndings is that both PZQ
and metrifonate are eﬃcacious and safe (Danso-
Appiah et al. 2008). The failure rate with the rec-
ommended standard dose of PZQ (40 mg/kg) is
0–37%, whilst that of metrifonate (3r7.5–10 mg/kg
given fortnightly) is 19–48% at one to three months
follow-up. However, no trial included in our analysis
directly compared the above-mentioned standard
doses, therefore precluding any head-to-head assess-
ment of the two treatments from currently available
data.
Although the eﬀects of PZQ against placebo are
obvious, for some comparisons between regimens
with both PZQ and metrifonate there was uncer-
tainty around their eﬀect estimates as shown by the
wide 95% CIs. The small sample size in some of the
trials may explain the levels of uncertainty. However,
the magnitude of the eﬀect is at times so dramatic
that it is unlikely that methodological quality alone
will have caused substantive biases to interfere with
the marked eﬀects and diﬀerences reported.
No diﬀerence was demonstrated with a single dose
of 20 or 30 mg/kg of PZQ compared to the standard
regimen (single oral dose of 40 mg/kg) in terms of all
outcomes measured in this review. Given the current
emphasis on controlling morbidity in high-burden
areas (WHO, 2002), andmorbidity, especially among
school-aged children, being associated with the num-
ber of eggs in an individual, this ﬁnding suggests
lower doses of PZQ may be eﬀective in morbidity
control. However, these results should be considered
with caution as detection error can play a role, es-
pecially when the studies are few and sample sizes are
small. While it is true that parasite load (with egg
counts often used as a proxymeasure) is an important
Table 2. Classiﬁcation of diﬀerent S. haematobium infection intensities in clinical trials included in a
Cochrane systematic review (Danso-Appiah et al. 2008), n.c. not classiﬁed
S. haematobium infection intensity (eggs/10 ml urine)
ReferenceLight Moderate Heavy
60–249 250–499 o500 Omer (1981)
250–500 501–1000 o1000 McMahon (1983)
1–5 6–50 >50 Rey, Nouhou and Sellin (1984)
1–29 30–99 100–500 Stephenson et al. (1985)
1–99 100–399 o400 King et al. (1988)
<100 n.c. o100 Taylor, Murare and Manomano (1988)
1–29 30–99 100–499 Stephenson et al. (1989)
1–99 100–399 o400 King et al. (1989); King et al. (2002)
1–49 n.c. o50 WHO (2002)
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factor in both morbidity for the individual patient
and environmental contamination (WHO, 2002), a
sub-curative dose may unduly put the drug under
selective pressure and favour parasite resistance
(Doenhoﬀ, 1998; Doenhoﬀ et al. 2008). Pharmaco-
kinetic data of diﬀerent doses of PZQ are few and old,
and have been obtained in healthy volunteers rather
than in schistosome-infected patients (Leopold et al.
1978). An exponential increase was found in the area
under the curve (AUC) with the PZQ dose in the
range of 5 to 50 mg/kg, with a six-fold increase from
20 to 50 mg/kg (Leopold et al. 1978). However, these
data do not come from infected patients, and hence
cannot be extrapolated so easily. This calls for well
designed trials incorporating also pharmacokinetic
assessment, possibly with sparse sampling and popu-
lation kinetic assessment. These trials should also
control for food intake, as the bioavailability of PZQ
depends upon taking it with food and the type of food
matters (Mandour et al. 1990; Castro et al. 2000).
The rationale behind the widely spaced dosing
intervals of metrifonate treatment derives from its
long-lasting eﬀect on red blood cells and plasma
cholinesterases (Plestina, Davis and Bailey, 1972).
However, the clinical signiﬁcance of this eﬀect and
why side eﬀects disappear during the ﬁrst 12–24
hours whereas the recovery of the enzymes takes
more than 4–6 weeks is not known (Plestina et al.
1972). Safety studies have shown no serious adverse
events in patients treated with 5–10 mg/kg metri-
fonate daily for 6–12 days (Snellen, 1981), and vari-
ous reviews of the toxicology and pharmacology
of metrifonate during its extensive use for urinary
schistosomiasis in the 1970s concluded that it had
very few adverse events (Holmstedt et al. 1978;
Feldmeier and Doehring, 1987; Cioli et al. 1995).
Also, metrifonate is currently used in Alzheimer’s
disease in extended regimens, and a systematic re-
view has concluded that overall tolerability is good
with only mild to moderate adverse events (Lo´pez-
Arrieta and Schneider, 2006). In the current review,
although drug safety was generally poorly reported
and assessed in few trials, no trial recorded a serious
adverse event, and no signiﬁcant diﬀerences in the
number and type of adverse events between metri-
fonate and PZQwere recorded, except for abdominal
pain that was more frequent after metrifonate. Opti-
mizing metrifonate treatment may provide a means
of easing drug pressure exerted on schistosomes by
the wide deployment of PZQ.
Immature schistosomes are less sensitive to PZQ
than adult worms (Sabah et al. 1986), which has
raised concern about controlling schistosomiasis
eﬀectively with this drug. Artemisinin derivatives
proved to be eﬀective against immature schistosomes
in laboratory studies (Utzinger et al. 2003, 2007).
However, this review shows that artesunate was not
eﬀective against S. haematobium infections (though
evidence was derived from a single trial (Borrmann
et al. 2001)), and combining artesunate and 40 mg/kg
PZQdid not improve eﬃcacy over PZQ alone. In two
non-randomised trials involving artesunate alone,
results were relatively better (De Clercq et al.
2002; Inyang-Etoh et al. 2004). The latter ﬁndings
were conﬁrmed in a recent trial ; artesunate alone
(4 mg/kg) resulted in a cure rate of 70.5%, whereas an
artesunate-PZQ combination obtained a cure rate
of 88.6% (Inyang-Etoh et al. 2009). Finally, a recent
trial in children under six years of age who were co-
infected with Plasmodium falciparum and S. haema-
tobium and who were treated with two diﬀerent
artemisinin-based combinations for malaria therapy
showed good eﬀects on S. haematobium. This trial,
however, could not be included in the current
analysis because there was no control group
(Boulanger et al. 2007).
The need for good trial methods
The validity of randomized controlled trials rests in
part on adequate allocation concealment andminimal
losses to follow-up, and weaknesses in both these
aspects were found in the trials included in the
current meta-analysis (Table 1). Without adequate
allocation concealment properly developed random
allocation sequences can be subverted (Schulz and
Grimes, 2002). A likely explanation for only four
trials (17%) included in our ﬁnal analyses adequately
concealing allocation is that this had not been
identiﬁed as a particularly relevant issue at the time
the trials were conducted (20–30 years ago). Even
after the publication of the CONSORT statement
(Begg et al. 1996) and despite continued educational
eﬀorts, the quality of reporting of randomized con-
trolled trials still needs improvement (Altman et al.
2001; Moher, Schulz and Altman, 2001).
The eﬀect of losing patients during follow-up on
randomisation is crucial as this relates to the internal
validity and the power of the trial. In our systematic
review we could not do a sensitivity analysis to
evaluate the eﬀect of loss to follow-up because data
were not suﬃcient. We encourage trialists to take
particular note of this issue and ensure that losses are
minimised and power is preserved in future trials.
Also, we welcome debate on the most appropriate
timing of follow-up in evaluating drug trials of both
urinary and intestinal schistosomiasis. The biology
of schistosomes suggests that treatment eﬀects with
antischistosomal drugs on parasitological parameters
should be evaluated during a window of four to eight
weeks post-treatment to avoid detecting the tail of
eggs released from dead worms on one side, and re-
infections on the other side. A ﬁrst attempt has
been made to evaluate this for intestinal schisto-
somiasis due to S. mansoni, and the authors con-
cluded that three weeks after PZQ administration is
an appropriate timing for drug eﬃcacy evaluation
(Scherrer et al. 2009).
Treatment of urinary schistosomiasis 1845
Safety is generally overlooked and when data are
available they are poorly reported. It is important
that trialists realise the importance of adequately
documenting and reporting on tolerability.
Diagnostic concerns
The quality of diagnosis can inﬂuence the observed
cure rates as clearly shown for both S. mansoni (de
Vlas and Gryseels, 1992; Booth et al. 2003) and
S. haematobium (N’Goran et al. 2003). Sensitivity
will aﬀect in particular the detection of light infec-
tions during follow-up. We found considerable vari-
ation in diagnostic criteria not only between, but also
within trials, also with regard to infection intensity.
This may be explained by the fact that the WHO
classiﬁcation as light (1–49 eggs/10 ml urine) and
heavy infection intensity (o50 eggs/10 ml urine) was
endorsed only recently (WHO, 2002) and was not in
use when the trials summarized here. Because of the
diﬀerent thresholds used for infection intensity, it
was not possible to combine and analyse the data
according to heavy infections, which is relevant to
morbidity control.
Study population issues
The age of participants enrolled in randomized con-
trolled trialsmay also inﬂuence results.Here, 22 trials
out of 24 recruited school-aged children. Hence the
overall eﬀect estimates as reported in this reviewmay
be lower than studies including all-age subjects, as
adults usually show lower infection intensities than
school-aged children and, conversely, higher treat-
ment eﬃcacies. This issue has been documented for
S.mansoni (Raso et al. 2004), and it is conceivable that
the same holds for S. haematobium. It should also be
noted that restricting treatment to school-aged chil-
dren leaves untreated adults and pre-school children
still excreting eggs to maintain transmission, if in-
deed transmission is a function of egg output. This
brings us to two important sets of considerations.
First, data should be reported separately for children
and adults before, if necessary, pooling the data to
assess overall eﬀects. Second, the purpose of studies
depends on the target population. Studies in children
receiving antischistosomal treatment are more apt
to assess the ‘true’ eﬃcacy of the drug because drugs
such as PZQ have an immune response-dependent
component (Doenhoﬀ et al. 1987), which is more
active in adults, while whole-population studies are
more suited to assess the programmatic eﬀectiveness
and eﬀects of control interventions.
IMPLICATIONS FOR POLICY
Both PZQ and metrifonate are eﬀective and safe
for treating urinary schistosomiasis. Our systematic
review and that of Lo´pez-Arrieta and Schneider
(2006) indicate that metrifonate is well tolerated.
Although in schistosomiasis control metrifonate has
operational drawbacks, notably multiple adminis-
trations, which make it less convenient for large-
scale morbidity control programmes than a single
dose of PZQ, the two drugs have similar eﬃcacy
proﬁles. Furthermore, considering that schisto-
somes are under intense and growing drug pressure
by PZQ and the inherent vulnerability of schisto-
somiasis control to parasite resistance, we suggest
metrifonate should be reconsidered for the treatment
of urinary schistosomiasis, to ease the drug pressure
on PZQ. This implies continued availability (pro-
duction and distribution) of the drug. It is also
important to have an alternative drug for treat-
ing urinary schistosomiasis should PZQ resistance
emerge.
Most of the trials contributing to this review were
conducted more than a decade ago, and entail a series
of methodological limitations. The new schisto-
somiasis trials must be conducted to contemporary
standards of clinical research paying particular at-
tention to quality issues we have raised, and adopt
commonly agreed criteria.
Our ﬁndings point to new approaches worth
being explored in well-designed trials such as: (1)
reassessing appropriate dosing schedules for me-
trifonate, including compliance and feasibility in
control programmes; (2) comparing standard me-
trifonate (3r7.5–10 mg/kg given fortnightly) and
PZQ (1r40 mg/kg) doses; (3) evaluating artemisi-
nin-based regimens and combination treatments
where appropriate (areas where malaria and schisto-
somiasis are not co-endemic); and (4) obtaining
pharmacokinetic/pharmacodynamic correlates for
PZQ.
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